Credit Suisse’s Pyxis Oncology PYXS Stock Holding History

Credit Suisse’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-152,018	Closed	-$299K	–	4094
2022 Q3	$299K	Sell	152,018 -813,447	-84%	-$2.13M	﹤0.01%	3082
2022 Q2	$2.3M	Buy	+965,465	New	+$2.57M	﹤0.01%	1815

Other funds holding PYXS

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Credit Suisse's PYXS Position: Q4 2022 in Review

Credit Suisse sold out of Pyxis Oncology (PYXS) in Q4 2022, closing a stake of 152,018 shares — an estimated $299K sold.

Credit Suisse first reported a position in PYXS in Q2 2022 and held it in 2 quarters. The position peaked at $2.3M in Q2 2022. 31 funds tracked by Wall St. Rank hold PYXS as of Q4 2022.

Credit Suisse reported no remaining Pyxis Oncology position as of Q4 2022 after selling out during the quarter.
Credit Suisse sold 152,018 Pyxis Oncology shares in Q4 2022, an estimated $299K.
Credit Suisse first reported a position in Pyxis Oncology in Q2 2022 and held it in 2 quarters.
Credit Suisse's Pyxis Oncology position peaked at $2.3M in Q2 2022.
31 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.